Clinical trial · Interventional
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
The Safety and Efficacy of Deferoxamine Combined With Conventional Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
NCT03652467CI-TRIAL-00037216unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional TACE | Drug | — | UNRESOLVED |
| Deferoxamine and conventional TACE | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Deferoxamine
- description
- Patients are treated with deferoxamine and conventional TACE.
- interventionNames
- Drug: Deferoxamine and conventional TACE
- type
- ACTIVE_COMPARATOR
- label
- Conventional TACE
- description
- Patients are treated with conventional TACE.
- interventionNames
- Drug: Conventional TACE
Primary outcomes (1)
- measure
- Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer
- timeFrame
- First dose to date of progressive disease or death due to any cause [every 3 cycles up to 36 months (1 cycle=2 weeks)]
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, ≥ 18 years of age. * The participant must have histologically-confirmed, unresectable HCC * At least 1 measurable lesion, and overall tumor lesions occupying \< 50% of liver volume * The participant has provided signed informed consent * No known allergy to contrast media * Not pregnant * No vascular anatomy or bleeding that would preclude catheter placement or emboli injection Exclusion Criteria: * Patients receiving concurrent radiotherapy or immunotherapy. * Patients who have received previous chemotherapy, biological agents, or radiotherapy. * Prior transarterial chemoembolisation (TACE) or transarterial embolisation (TAE). * Prior liver transplantation or liver resection. * Current or recent (within 10 days of study start) use of full-dose anticoagulants for therapeutic purposes. * Patients with high risk esophageal/gastric varices. * The participant has central nervous system (CNS) metastases or carcinomatous meningitis * The participant has poorly-controlled hypertension \[in other words (ie), blood pressure in abnormal range despite medical management\]
References
Publications (0)
Data not yet available
No reference posted for this study.